TuHURA is targeting the achievement of the following potential milestones for the remainder of 2024 and 2025: Q4 2024: Reach a potential definitive agreement for acquisition of KVA12123 VISTA inhibiting antibody via merger with Kineta, subject to continuing diligence and negotiations with Kineta; H1 2025: Initiate IFx-2.0 Phase 3 trial; H1 2025: IFx-2.0 Inhibitor Resistant “basket” trial; H1 2025: Complete potential acquisition of transaction involving Kineta’s KVA12123; H2 2025: Commence VISTA inhibiting Mab Phase 2 trials; H2 2025: Bi-specific MDSC targeted ADC in vivo POC; H2 2025: IFx-3.0: CD22+ tumor targeted mRNA in vivo POC studies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HURA: